News – Page 80 – Endpoints News

Q3 biotech roundup: The 2024 turnaround sputters into a critical Q4 finale

6 months ago

Novo declares Phase 3 cardiac outcomes trial win for oral GLP-1

6 months ago

Septerna outlines $157M IPO after entering the clinic with GPCR pipeline

6 months ago

Catalent moves to reassure customers about what happens after merger

6 months ago

Former Karuna crew quickly assembles $225M for next neuro bet at Seaport

6 months ago

Vertex shares full pivotal non-opioid pain data, showing better safety than placebo

6 months ago

A Q&A with a Nobel Prize winner; Pfizer meets with Starboard; J&J reports Q3 earnings; and more

6 months ago

NJ judge tosses Novartis' IRA lawsuit in another win for government

6 months ago

Lykos is optimistic about MDMA treatment after meeting with FDA

6 months ago

FDA won't take action against GLP-1 compounders as it rethinks tirzepatide shortage

6 months ago

FDA approves Astellas' gastric cancer drug Vyloy ahead of schedule

6 months ago

Apertura and Atalanta reduce headcount en route toward the clinic

6 months ago

EMA again recommends against authorization for PTC Therapeutics' Translarna

6 months ago

European Commission to work more closely with European Medicines Agency

6 months ago

A conversation with Nobel Prize winner David Baker on the future of AI in protein design — and beyond

6 months ago

FDA partially holds BioNTech's Phase 3 anti-CTLA-4, company pauses enrollment

6 months ago

Aura’s bladder cancer data; Poseida discloses $15M milestone from Roche

6 months ago

Shanghai biotech’s VEGF bispecific enters Phase 1 trial in China

6 months ago

Gilead pulls Trodelvy's accelerated label in bladder cancer after drug failed confirmatory study

6 months ago

Consumer and union groups call on FTC to ‘challenge’ Novo-Catalent deal

6 months ago

Pfizer ends trial of Array-acquired SHP2 inhibitor after similar cuts from peers

6 months ago

CVS replaces CEO Karen Lynch with PBM exec David Joyner

6 months ago

Supernus’ depression drug shows ‘rapid’ onset in mid-stage test

6 months ago

Exclusive: Ex-Affimed CEO heads to UK nanomedicine biotech; Jami Rubin leaves Boundless Bio after IPO

6 months ago

First page Previous page 77 78 798081 82 83 Next page Last page